Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma

被引：0
|
作者：
Hideki Goto
Shinichi Makita
Koji Kato
Kota Tokushige
Taizo Fujita
Koichi Akashi
Koji Izutsu
Takanori Teshima
机构：
[1] Hokkaido University Faculty of Medicine,Department of Hematology, Graduate School of Medicine
[2] National Cancer Center Hospital,Department of Hematology
[3] Kyushu University Graduate School of Medical Sciences,Department of Medicine and Biosystemic Science
[4] Novartis Pharma K.K.,undefined
来源：
International Journal of Clinical Oncology | 2020年 / 25卷
关键词：
Tisagenlecleucel; CAR T-cell therapy; Diffuse large B-cell lymphoma; JULIET;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1736 / 1743
页数：7
相关论文
共 50 条
  • [41] Long-Term Follow-up of Tisagenlecleucel in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Updated Analysis of Juliet Study
    Schuster, Stephen J.
    Bishop, Michael R.
    Tam, Constantine S.
    Borchmann, Peter
    Jaeger, Ulrich
    Waller, Edmund K.
    Holte, Harald
    McGuirk, Joseph
    Jaglowski, Samantha
    Tobinai, Kensei
    Andreadis, Charalambos
    Fleury, Isabelle
    Mielke, Stephan
    Teshima, Takanori
    Westin, Jason R.
    Bachanova, Veronika
    Foley, Stephen Ronan
    Ho, Joy
    Magenau, John M.
    Wagner-Johnston, Nina
    Kato, Koji
    Kersten, Marie Jose
    van Besien, Koen
    Chu, Jufen
    Jary, Aline
    Anak, Oezlem
    Salles, Gilles A.
    Maziarz, Richard T.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [42] COST-EFFECTIVENESS OF TISAGENLECLEUCEL FOR ADULTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA : A CANADIAN SOCIETAL PERSPECTIVE
    Yang, H.
    Qi, C.
    Zhang, J.
    El Ouagari, K.
    VALUE IN HEALTH, 2018, 21 : S44 - S44
  • [43] Polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma
    Dietliker, N.
    Kiesel, H.
    Mueller, R.
    Mueller, A. M.
    Manz, M. G.
    Zenz, T.
    Rosler, W.
    SWISS MEDICAL WEEKLY, 2020, : 21S - 21S
  • [44] Novel agents in relapsed/refractory diffuse large B-cell lymphoma
    Varma, Gaurav
    Goldstein, Jordan
    Advani, Ranjana H.
    HEMATOLOGICAL ONCOLOGY, 2023, 41 : 92 - 106
  • [45] Clinical pharmacology of tisagenlecleucel (CTL019) in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)
    Awasthi, Rakesh
    Tam, Constantine S.
    Jaeger, Ulrich
    Jaglowski, Samantha
    Foley, Stephen Ronan
    van Besien, Koen
    Wagner-Johnston, Nina D.
    Kersten, Maria Jose
    Schuster, Stephen J.
    Salles, Gilles
    Maziarz, Richard T.
    Anak, Ozlem
    Pacaud, Lida Bubuteishvili
    Gazi, Lucien
    Waldron, Edward
    Hamilton, Jason
    Pruteanu, Iulian
    Tai, Feng
    Mueller, Karen Thudium
    Waller, Edmund K.
    CANCER RESEARCH, 2018, 78 (13)
  • [46] Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Harris, Leonard Jeff
    Patel, Kruti
    Martin, Michael
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (22) : 1 - 12
  • [47] Phylogenetic Evolution in Refractory/Relapsed Diffuse Large B-Cell Lymphoma
    Ruminy, Philippe
    Rainville, Vinciane
    Mareschal, Sylvain
    Etancelin, Pascaline
    Joly, Berangere
    Picquenot, Jean-Michel
    Bastard, Christian
    Tilly, Herve
    Jardin, Fabrice
    BLOOD, 2012, 120 (21)
  • [48] Relapsed or Refractory Diffuse Large B-Cell Lymphoma: "Dazed and Confused"
    Kesireddy, Meghana
    Lunning, Matthew A.
    ONCOLOGY-NEW YORK, 2022, 36 (06): : 360 - 369
  • [49] Polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma
    Dietliker, N.
    Kiesel, H.
    Mueller, R.
    Mueller, A. M.
    Manz, M.
    Zenz, T.
    Rosler, W.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 66 - 67
  • [50] Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
    Salles, Gilles
    Dlugosz-Danecka, Monika
    Ghesquieres, Herve
    Jurczak, Wojciech
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (04) : 455 - 463
12345